IMUX Stock Summary and Trading Ideas (Immunic | NASDAQ:IMUX)

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Immunic trades on the NASDAQ stock market under the symbol IMUX.

As of September 23, 2026, IMUX stock price declined to $9.37 with 655,477 million shares trading.

IMUX has a beta of 0.41, meaning it tends to be less sensitive to market movements. IMUX has a correlation of 0.00 to the broad based SPY ETF.

IMUX has a market cap of $127.85 million. This is considered a Micro Cap stock.

In the last 3 years, IMUX traded as high as $21.10 and as low as $5.06.

The top ETF exchange traded funds that IMUX belongs to (by Net Assets): VTI, VXF, SBIO, AVSC, QQQS.

IMUX has underperformed the market in the last year with a price return of +3.1% while the SPY ETF gained +16.3%. IMUX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -36.5% and -26.5%, respectively, while the SPY returned +3.4% and +0.5%, respectively.

IMUX support price is $10.29 and resistance is $11.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMUX shares will trade within this expected range on the day.